|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Breast carcinoma: Updates in molecular
profiling 2018. Clin Lab Med. 38:401–420. 2018.
|
|
3
|
Cheng CW, Yu JC, Hsieh YH, Liao WL, Shieh
JC, Yao CC, Lee HJ, Chen PM, Wu PE and Shen CY: Increased cellular
levels of microRNA-9 and microRNA-221 correlate with cancer
stemness and predict poor outcome in human breast Cancer. Cell
Physiol Biochem. 48:2205–2218. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mansoori B, Mohammadi A, Shirjang S and
Baradaran B: HMGI-C suppressing induces P53/caspase9 axis to
regulate apoptosis in breast adenocarcinoma cells. Cell Cycle.
15:2585–2592. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mansoori B, Mohammadi A, Goldar S,
Shanehbandi D, Mohammadnejad L, Baghbani E, Kazemi T, Kachalaki S
and Baradaran B: Silencing of high mobility group isoform IC
(HMGI-C) enhances paclitaxel chemosensitivity in breast
adenocarcinoma cells (MDA-MB-468. Adv Pharm Bull. 6:171–177. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raval GN, Bharadwaj S, Levine EA,
Willingham MC, Geary RL, Kute T and Prasad GL: Loss of expression
of tropomyosin-1, a novel class II tumor suppressor that induces
anoikis, in primary breast tumors. Oncogene. 22:6194–203. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volinsky N, McCarthy CJ, von Kriegsheim A,
Saban N, Okada-Hatakeyama M, Kolch W and Kholodenko BN: Signalling
mechanisms regulating phenotypic changes in breast cancer cells.
Biosci Rep. 35:e001782015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sauter ER: Breast cancer prevention:
Current approaches and future Directions. Eur J Breast Health.
14:64–71. 2018.PubMed/NCBI
|
|
9
|
Zhuo D and Li X: Biological roles of
aberrantly expressed glycosphingolipids and related enzymes in
human cancer development and progression. Front Physiol. 9:4662018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bronchud MH, Tresserra F and Zantop BS:
Epigenetic changes found in uterine decidual and placental tissues
can also be found in the breast cancer microenvironment of the same
unique patient: description and potential interpretations.
Oncotarget. 9:6028–6041. 2017.
|
|
11
|
Jovanovic J, Rønneberg JA, Tost J and
Kristensen V: The epigenetics of breast cancer. Mol Oncol.
4:242–254. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weidle UH, Dickopf S, Hintermair C,
Kollmorgen G, Birzele F and Brinkmann U: The role of micro RNAs in
breast cancer metastasis: Preclinical validation and potential
therapeutic targets. Cancer Genomics Proteomics. 15:17–39.
2018.
|
|
13
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
14
|
Dworkin AM, Huang THM and Toland AE:
Epigenetic alterations in the breast: Implications for breast
cancer detection, prognosis and treatment. Semin Cancer Biol.
19:165–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hosseinahli N, Aghapour M, Duijf PHG and
Baradaran B: Treating cancer with microRNA replacement therapy: A
literature review. J Cell Physiol. 233:5574–5588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sieuwerts AM, Mostert B, Bolt-de Vries J,
Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van
Galen A, de Weerd V, et al: mRNA and microRNA expression profiles
in circulating tumor cells and primary tumors of metastatic breast
cancer patients. Clin Cancer Res. 17:3600–3618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ranji N, Sadeghizadeh M, Karimipoor M,
Shokrgozar MA and Ebrahimzadeh-Vesal R: AKT family and miRNAs
expression in IL-2 induced CD4(+) T cells. Iran J Basic Med Sci.
17:886–894. 2014.
|
|
18
|
Blondal T, Jensby Nielsen S, Baker A,
Andreasen D, Mouritzen P, Wrang Teilum M and Dahlsveen IK:
Assessing sample and miRNA profile quality in serum and plasma or
other biofluids. Methods. 59:S1–S6. 2013. View Article : Google Scholar
|
|
19
|
Ranji N, Sadeghizadeh M, Shokrgozar MA,
Bakhshandeh B, Karimipour M, Amanzadeh A and Azadmanesh K:
MiR-17-92 cluster: An apoptosis inducer or proliferation enhancer.
Mol Cell Biochem. 380:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng D, Yang S, Wan X, Zhang Y, Huang W,
Zhao P, Li T, Wang L, Huang Y, Li T and Li Y: A transcriptional
target of androgen receptor, miR-421 regulates proliferation and
metabolism of prostate cancer cells. Int J Biochem Cell Biol.
73:30–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan Y, Jiao G, Wang C, Yang J and Yang W:
MicroRNA-421 inhibits breast cancer metastasis by targeting
metastasis associated 1. Biomed Pharmacother. 83:1398–1406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang Z, Guo J, Xiao B, Miao Y, Huang R,
Li D and Zhang Y: Increased expression of miR-421 in human gastric
carcinoma and its clinical association. J Gastroenterol. 45:17–23.
2010. View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
25
|
Mehrgou A and Akouchekian M: Therapeutic
impacts of microRNAs in breast cancer by their roles in regulating
processes involved in this disease. J Res Med Sci. 22:1302017.
View Article : Google Scholar
|
|
26
|
Petrovic N and Ergun S: miRNAs as
potential treatment targets and treatment options in cancer. Mol
Diagn Ther. 22:157–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu J, Li G, Yao Y, Wang Z, Sun W and Wang
J: MicroRNA-421 is a new potential diagnosis biomarker with higher
sensitivity and specificity than carcinoembryonic antigen and
cancer antigen 125 in gastric cancer. Biomarker. 20:58–63. 2015.
View Article : Google Scholar
|
|
28
|
Wu JH, Yao YL, Gu T, Wang ZY, Pu XY, Sun
WW, Zhang X, Jiang YB and Wang JJ: MiR-421 regulates apoptosis of
BGC-823 gastric cancer cells by targeting caspase-3. Asian Pac J
Cancer Prev. 15:5463–5468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao J, Zhang S, Zhou Y, Liu C, Hu X and
Shao C: MicroRNA-421 suppresses DPC4/Smad4 in pancreatic cancer.
Biochem Biophys Res Commun. 406:552–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lankat-Buttgereit B and Göke R: The tumour
suppressor Pdcd4: recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Göke R, Gregel C, Göke A, Arnold R,
Schmidt H and Lankat-Buttgereit B: Programmed cell death protein 4
(PDCD4) acts as a tumor suppressor in neuroendocrine tumor cells.
Ann N Y Acad Sci. 1014:220–221. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang HS, Jansen AP, Komar AA, Zheng X,
Merrick WC, Costes S, Lockett SJ, Sonenberg N and Colburn NH: The
transformation suppressor Pdcd4 is a novel eukaryotic translation
initiation factor 4A binding protein that inhibits translation. Mol
Cell Biol. 23:26–37. 2003. View Article : Google Scholar :
|
|
33
|
Yang HS, Cho MH, Zakowicz H, Hegamyer G,
Sonenberg N and Colburn NH: A novel function of the MA-3 domains in
transformation and translation suppressor Pdcd4 is essential for
its binding to eukaryotic translation initiation factor 4A. Mol
Cell Biol. 24:3894–3906. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang HS, Jansen AP, Nair R, Shibahara K,
Verma AK, Cmarik JL and Colburn NH: A novel transformation
suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB
or ODC transactivation. Oncogene. 20:669–676. 2011. View Article : Google Scholar
|
|
35
|
Goke R, Barth P, Schmidt A, Samans B and
Lankat-Buttgereit B: Programmed cell death protein 4 suppresses
CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell
Physiol. 287:C1541–C1546. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Z, Wang J, Li J, Wang X and Song W:
MicroRNA-150 promotes cell proliferation, migration, and invasion
of cervical cancer through targeting PDCD4. Biomed Pharmacother.
97:511–517. 2018. View Article : Google Scholar
|
|
37
|
Schmid T, Jansen AP, Baker AR, Hegamyer G,
Hagan JP and Colburn NH: Translation inhibitor Pdcd4 is targeted
for degradation during tumor promotion. Cancer Res. 68:1254–1260.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wen YH, Shi X, Chiriboga L, Matsahashi S,
Yee H and Afonja O: Alterations in the expression of PDCD4 in
ductal carcinoma of the breast. Oncol Rep. 18:1387–1393.
2007.PubMed/NCBI
|
